In a retrospective study by Miodovnik et al., the clinical outcomes of 84 patients with cutaneous squamous cell carcinoma (cSCC) treated with anti–PD-1 immunotherapy (cemiplimab or pembrolizumab) at a single tertiary referral center were analyzed. Here, RPL17 is linked to skin squamous cell carcinoma.